Rebate on Prescription Drugs

Illuminating article; must read. Here are two sentences that capture the essence of this issue: “In 2016, leading products in these classes had total pre-rebate spending in Part D of $2.5 billion (Lantus Solostar) and $4.4 billion (Harvoni). For an individual patient, this would reduce list prices on which their deductibles and co-insurance are calculated from $417 to $142 for patients filling a 1-month supply for Lantus Solostar and from $92 648 to $35 206 for patients filling an 84-day course of treatment with Harvoni, assuming class-level rebates applied to these products.”